The post-discharge suicide risk among psychiatric patients is significantly higher than it among patients with other diseases and general population. The brief contact interventions (BCIs) are recommended to decrease the risk in areas with limited mental health service resource like China, however the best frequency to implement BCIs is unknown. This implementation study aims to 1) to develop an intervention strategy against post-discharge suicide based on BCIs for Chinese psychiatric patients; 2) to determine the best frequency of BCIs based on Sequential Multiple Assignment Randomized Trial; 3) to evaluate the effectiveness of the intervention strategy and explore its implementability based on the Implementation Outcome Framework (IOF). Based on the community-based participatory research (CBPR) approach, this study will invite psychiatric patients and family members, psychiatrist and nurses, community mental health workers and social workers as the community team to develop a post-discharge suicide intervention strategy. The study will recruit patients with psychotic symptoms and with major depressive disorder discharged from Shenzhen Kangning Hospital (SKH) in a Sequential Multiple Assignment Randomized Trial (SMART) to determine the best frequency for implementing BCIs and to evaluate the effectiveness. Participants will be randomized into two intervention groups to receive BCIs at different frequencies. Follow-ups to evaluate participants' suicide risk are scheduled at 1, 3, 6 and 12 months after discharge. The re-randomization will be applied at 3 months after discharge. With the Intent-to-treat (ITT) approach, generalized estimating equation (GEE) and survival analysis (SA) will be applied to compare the effectiveness among groups and to explore factors associated with suicide risk. Meanwhile, this study will collect qualitative and quantitative information on implementation and service outcomes from the community team.
This is a mixed-methods study with two stages. The first stage is to develop the intervention strategy by individual in-depth and focus groups interviews; and the second stage is to implement the strategy and evaluate the implementation quantitatively by a randomized trial and qualitatively by focus group interviews.
The investigators categorize the community team into three sub-groups, the patients-LHSs group, the clinic mental health service provider group (psychiatrists and nurses, and psycho-crisis intervention team members), and the community mental health service provider group (community mental health workers and mental health social workers).
1.1 Intervention development The investigators will conduct three focus group interviews in each sub-group and ten to fifteen cases of individual in-depth interview with the community to avoid bias in focus groups and to protect privacy related to personal experience in suicide and suicide intervention. The themes include: 1) key points in suicide risk management after discharge, 2) how to develop BCIs content and delivery BCIs appropriately and feasibly to increase social connectedness and social support, 3) how to improve compliance to treatment and increase subsequent visits after discharge. There will be scheduled meetings with the community to discuss and revise the intervention strategy before implementation.
1.2 Implementation evaluation Based on IOF, the investigators will conduct three focus group interviews in each sub-group to explore 1) patients' and LHSs' attitudes, acceptability, and understanding of the strategy, 2) the clinic and community mental health service providers' willingness, feasibility and sustainability to implement the strategy, 3) the effectiveness, efficiency, equity, safety and timeliness of the strategy and whether it is patient-centered.
1.3 The qualitative study sample Purposive sampling will be applied to recruit participants for the community team. For each type of sub-group, there will be five to eight members.
2. The sequential multiple assignment randomized trial The investigators will conduct the sequential multiple assignment randomized trial (SMART) to determine the best frequency to implement BCIs and investigate the patient outcomes in IOF. The SMART design reflects the idea of adaptive treatment strategies and dynamic treatment regimens that provide a sequence of decisions about the points at which to offer different interventions and a set of intervention options for each decision point. There will be two stages of treatment.
Stage 1: After recruitment and baseline survey, participants will be randomized into Group 1 and Group 2 where BCIs will be implemented monthly and weekly, respectively. Because suicide risk is the highest in the first three months among discharged psychiatric patients, the investigators set the check point at three months after discharge to assess participants' suicide risk in both groups.
Stage 2: At the check point, for participants in Group 1, if the suicide risk increased, they will be re-randomized into Group 1a and Group 1b where BCIs will be implemented weekly and bi-weekly, respectively; if the suicide risk decreased or did not change, they will remain receiving BCIs monthly as Group 1c. For participants in Group 2, if the suicide risk increased or did not change, they will remain receiving BCIs weekly as Group 2a; if the suicide risk decreased, they will be re-randomized into Group 2b and Group 2c where BCIs will be implemented monthly and bi-weekly, respectively. After the re-randomization, participants will continue to receive BCIs until 12 months after discharge, and the suicide risk will be evaluated at 1, 3, 6 and 12 months after discharge.
2.1 The quantitative study sample The investigators plan to implement the strategy in patients with psychotic symptoms and patients with major depressive disorder (MDD), as in representative of severe and non-severe mental disorders, separately.
2.2 Sample size The sample size was calculated to estimate the primary effect in SMART trial. The investigators set the rate of type I error α at 0.05, the rate of type II error β at 0.20, the power (1-β) at 0.80, the moderate effect size d at 0.3566, and the sample size is 130 for Group 1 and Group 2, 260 in total; considering dropout, the sample size will be increased by 20%, and the final sample size is 312 participants. The investigators will conduct two SMART trials in patients with psychotic symptoms and MDD separately, and the sample size for each trial is 312 (624 patients in total).
2.3 Randomization and mask After recruitment and the baseline survey, participants will be assigned into Group 1 and Group 2 by simple randomization in R program. At the check point in the SMART trial, participants will be re-assigned into Group 1a, Group 1b, Group 1c, Group 2a, Group 2b, and Group 2c based on their suicide risk by simple randomization in R program. The allocation ratio in randomization will be 1:1. Participants, LHSs, nurses who perform recruitment and baseline survey, and investigators who perform follow-ups will be blinded to the assignment.
2.4 Brief contact intervention The BCI in this study is a series of structured messages. Messages will be delivered to participants by pushing feeds through WeChat and an iOS/Android application developed for this study. If participants did not use smartphones, messages will be delivered by mobile text messages or by phone calls. Though the final details is yet to be determined by the CBPR study, the investigators expect to structure messages into six components including introduction, greetings for previous complains, mental health promotion, encouragement, and coping strategies, remind of treatment and subsequent visit, and crisis intervention resource.
Noted, the same messages will also be sent to patients' LHSs to remind patients through their families for subsequent visits and upcoming follow-up surveys, and to remind LHSs that patients are at risk of post-discharge suicide and need attention and care, and the necessities of seeking crisis intervention in a timely manner.
2.5 Data collection To evaluate post-discharge suicide risk more cautiously and to provide crisis intervention in time, we will conduct face-to-face interview to collect information. After research assistants introduce the study and obtain written informed consent, trained nurses in SKH will recruit participants and perform baseline survey before discharge. As mentioned, we encourage subsequent visits to SKH out-patient clinics in BCIs, and research assistants will contact participants to schedule out-patient visits and complete follow-up surveys during the visits at 1, 3, 6 and 12 months after discharge. If participants refused follow-ups in out-patient settings, we would schedule home visits to complete the survey by research assistants and community mental health workers. If patients did not respond, research assistants will contact their LHSs to obtain participants' recent updates and help them schedule out-patient visits for patients if necessary. Dropout is defined as 1) participants or their LHSs request to quit the study and stop receiving any brief contact messages; 2) participants or their LHSs refuse follow-up surveys either at out-patient clinics or at home; 3) participants pass away by accidents or other health problems except suicide. Particularly, at each time point of follow-ups, we will contact patients and LHSs up to three times. If neither of them responded, they would be treated as dropout.
3. Study outcomes and measurements The implementation outcomes of the overall project are based on the Implementation Outcomes Framework, in which primary and secondary outcomes of the SMART trial will be collected at 1, 3, 6 and 12 months after discharge.
Condition | Suicide |
---|---|
Treatment | Brief contact intervention |
Clinical Study Identifier | NCT04907669 |
Sponsor | Shenzhen Kangning Hospital |
Last Modified on | 27 April 2022 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.